Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis
- PMID: 11596160
- DOI: 10.1002/ppul.1144
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis
Abstract
A thorough understanding of the early natural history of cystic fibrosis (CF) lung disease is critical for the development of effective interventions in the youngest patients. We assessed the evolution of pulmonary infection, inflammation, and clinical course among 40 infants over a 2-year period through annual bronchoalveolar lavage (BAL) for culture and measurements of pro- and anti-inflammatory cytokines, semiannual infant pulmonary function testing, and quarterly clinical evaluations. Both the prevalence of CF pathogens and their density in BAL fluid increased with age. Infants had neutrophilic lower airway inflammation and elevated IL-8 concentrations independent of whether CF pathogens were recovered. Total leukocyte and neutrophil densities and IL-8 concentrations increased with density of CF pathogens in BAL fluid, whether the isolated organism was P. aeruginosa or another pathogen. IL-10 concentrations were similar in CF subjects and non-CF historical controls. Infants generally had suboptimal growth (low weight and height percentiles) and obstructive lung disease (decreased expiratory flows and air trapping). Subjects from whom CF pathogens were isolated at > 10(5) cfu/mL had the worst air trapping and lowest Brasfield chest X-ray scores. Our findings provide a foundation for future studies of early intervention in CF lung disease, including antimicrobial and anti-inflammatory therapy.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Lower airway inflammation in infants with cystic fibrosis detected by newborn screening.Pediatr Pulmonol. 2005 Dec;40(6):500-10. doi: 10.1002/ppul.20294. Pediatr Pulmonol. 2005. PMID: 16208679
-
Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.Am J Respir Crit Care Med. 2002 Apr 1;165(7):904-10. doi: 10.1164/ajrccm.165.7.2010139. Am J Respir Crit Care Med. 2002. PMID: 11934712
-
The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis.Thorax. 2017 Dec;72(12):1104-1112. doi: 10.1136/thoraxjnl-2016-209279. Epub 2017 Mar 9. Thorax. 2017. PMID: 28280235
-
Disease surveillance using bronchoalveolar lavage.Paediatr Respir Rev. 2008 Sep;9(3):151-9. doi: 10.1016/j.prrv.2008.01.002. Epub 2008 Jul 30. Paediatr Respir Rev. 2008. PMID: 18694706 Review.
-
Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.Paediatr Drugs. 2005;7(6):353-63. doi: 10.2165/00148581-200507060-00004. Paediatr Drugs. 2005. PMID: 16356023 Review.
Cited by
-
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.J Cyst Fibros. 2013 Mar;12(2):147-53. doi: 10.1016/j.jcf.2012.08.001. Epub 2012 Sep 1. J Cyst Fibros. 2013. PMID: 22944725 Free PMC article. Clinical Trial.
-
[MRI in mucoviscidosis (cystic fibrosis)].Radiologe. 2006 Apr;46(4):275-6, 278-81. doi: 10.1007/s00117-005-1308-9. Radiologe. 2006. PMID: 16437239 Review. German.
-
Inducible NO synthase expression is low in airway epithelium from young children with cystic fibrosis.Thorax. 2006 Jun;61(6):514-20. doi: 10.1136/thx.2005.054643. Epub 2006 Mar 3. Thorax. 2006. PMID: 16517573 Free PMC article.
-
Abnormalities in the pulmonary innate immune system in cystic fibrosis.Am J Respir Cell Mol Biol. 2006 Mar;34(3):364-74. doi: 10.1165/rcmb.2005-0146OC. Epub 2005 Nov 17. Am J Respir Cell Mol Biol. 2006. PMID: 16293782 Free PMC article.
-
Antigen specificity and cross-reactivity drive functionally diverse anti-Aspergillus fumigatus T cell responses in cystic fibrosis.J Clin Invest. 2023 Mar 1;133(5):e161593. doi: 10.1172/JCI161593. J Clin Invest. 2023. PMID: 36701198 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical